Pain Management

The placebo effect is growing stronger in US clinical trials for chronic pain medications, according to a recent study.

Citing a rare, yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol in the pediatric population.

Touted as a way to reduce pain, speed injury recovery, and improve mood, cryotherapy involves exposing the body to temperatures up to minus 300 degrees Fahrenheit.

Patients take acetaminophen and ibuprofen for minor pain and fever, but are they interchangeable?

Many sleepwalkers who injure themselves during their sleep do not experience pain until the next morning, which may lead them to the pharmacy for OTC pain relief.

The FDA has accepted Espero Pharmaceuticals' new drug application for GoNitro, a product designed to treat an attack or prophylaxis of angina pectoris due to coronary artery disease.

Treating low back pain with physical therapy soon after symptoms start does not make a clinically important difference when compared with starting therapy later.

The FDA has approved Endo Pharmaceuticals and BioDelivery Sciences' buprenorphine buccal film (Belbuca) for the management of chronic pain.

Pain is recognized as a common, but complex, multifaceted experience that can interfere with quality of life and contribute to psychological problems, social awkwardness, and work-related disability.

A recent study has found that brain inflammation caused by chronic nerve pain alters activity in the mood-regulating regions of the brain.

Black children with severe pain are less likely to receive opioids in emergency rooms than white children.

The placebo effect is growing stronger in US clinical trials for chronic pain medications.

When you have 99.99% awesome patients, a pharmacist's job is fun to do.

Citing a rare yet serious risk of slowed breathing, the FDA is evaluating the use of the opioid pain medication tramadol (Ultram, Ultram ER, Conzip) in the pediatric population.

Pregabalin and gabapentin are often considered first-line treatments for various neuropathic pain syndromes, generally irrespective of cause.

Draft guidelines from the US Centers for Disease Control and Prevention (CDC) could sharply reduce the role opioids play in primary care-based pain management.

Through a partnership between the St. Louis College of Pharmacy (STLCOP) and Washington University School of Medicine in St. Louis, the new Center for Clinical Pharmacology in Missouri will work toward improving pain treatment.

This Continuing Education activity is supported by an educational grant from Mallinckrodt.

The US Department of Health and Human Services (HHS) is making it easier for patients with shoulder injury related to vaccine administration (SIRVA) to be compensated for their pain.

The Drug Enforcement Administration (DEA) recently made an appearance at a state pharmacy board meeting to appease pharmacists' fears of a crackdown on pharmacies.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause severe and disabling joint pain, the FDA has warned.

The FDA has accepted Allergan's resubmission to approve the use of onabotulinumtoxinA (Botox) for lower limb spasticity in adults.

A pharmacist's perspective of OxyContin's approval for use in patients ages 11 to 16.

The FDA has expanded the use of the powerful painkiller oxycodone (OxyContin) for children as young as 11.

Pharmacists can have a positive impact by identifying and helping patients in pain.